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Abstract
Alzheimer’s disease (AD) is characterized by amyloid-b (Ab) deposition in the brain, neuronal cell loss and cognitive decline. We
show here that retinoic acid receptor (RAR)a signalling in vitro can prevent both intracellular and extracellular Ab accumulation. RARa
signalling increases the expression of a disintegrin and metalloprotease 10, an a-secretase that processes the amyloid precursor
protein into the non-amyloidic pathway, thus reducing Ab production. We also show that RARa agonists are neuroprotective, as they
prevent Ab-induced neuronal cell death in cortical cultures. If RARa agonists are given to the Tg2576 mouse, the normal Ab
production in their brains is suppressed. In contrast, neither RARb nor c-agonists affect Ab production or Ab-mediated neuronal cell
death. Therefore, RARa agonists have therapeutic potential for the treatment of AD.
Introduction
The pathological hallmarks of Alzheimer’s disease (AD) are the
presence of senile plaques containing amyloid-b (Ab) peptide and the
formation of neuronal tangles in the cerebral cortex. In addition,
intraneuronal formation of Ab has been shown to be involved in AD
(LaFerlaet al.,2007).Abisderivedfromtheamyloidprecursorprotein
(APP), which can also be processed into a non-amyloidic pathway
(Thinakaran&Koo,2008).Intheamyloidicpathway,APPiscleavedby
b-secretase and then c-secretase to give Ab (Thinakaran & Koo, 2008).
In the non-amyloidic pathway, a-secretase cleaves the APP within the
Absequence,liberatingsecretoryAPP(sAPP)a;cleavagebyc-secretase
then liberates the non-toxic peptide p3 (Thinakaran & Koo, 2008).
In AD, there are genetic linkages to the disease that are close to
genes involved in the retinoid signalling pathway (Goodman &
Pardee, 2003). This pathway is mediated by retinoic acid (RA)
receptors (RARs) and retinoid X receptors (RXRs), both of which
have three types, a, b and c, and various isoforms (Bastien &
Rochette-Egly, 2004). Transcription occurs when the small lipophilic
molecule RA binds to an RAR–RXR heterodimer, which then binds to
RA response elements located in the regulatory regions of target genes
(Bastien & Rochette-Egly, 2004).
RA is derived from vitamin A, and we have shown that a deﬁciency
in rats leads to Ab deposits in the brain vasculature and neuronal cell
death (Corcoran et al., 2004). This was correlated with the lack of
RARa signalling, as this receptor is downregulated in vitamin A-
deﬁcient rats, and the same receptor deﬁcit is found in the cortices in
pathology samples of AD patients (Corcoran et al., 2004). Recent
work has also shown that all-trans RA (atRA) applied intraperitoneally
in a mouse model of AD results in a decrease in Ab production (Ding
et al., 2008), but the speciﬁc RAR involved in this process was not
identiﬁed. If retinoids are to be used as therapeutic agents for AD, it is
important to identify the speciﬁc RAR(s) involved in this process in
order to discover relevant drug targets, thus overcoming deﬁciencies
in atRA, which can activate all of the RARs, with potential toxic
effects. Although the retinoid agonists used here are not approved as
drugs, they can act as starting points for effective therapeutics.
In this study, we show in vitro that both intracellular and
extracellular Ab production and the neuronal cell death associated
with Ab can be prevented by RARa signalling, and that there is
induction of a disintegrin and metalloproteinase (ADAM)10, which
has been shown to act as an a-secretase (Lammich et al., 1999; Endres
et al., 2005), and whose modulation may be an opportunity for the
treatment of AD (Endres & Fahrenholz, 2010). In addition, we show
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European Journal of Neurosciencethat an RARa agonist can cross the blood–brain barrier (BBB) and that
RARa agonists administered to Tg2576 mice either intraperitoneally
or orally can prevent Ab production via an upregulation of ADAM10.
Materials and methods
Neuronal cultures
Cortical neurons were isolated from embryonic day 15 mice (NIH
Swiss; Harlen, Bicester, UK). The brains were removed from the
embryos, and washed three times in phosphate-buffered saline (PBS)–
1.5% glucose. Cortices with their meninges removed were then
triturated through a 21G needle in the presence of PBS–1.5% glucose.
The dissociated cells were then left for 5 min on ice to allow debris to
settle. The supernatant was transferred to a 15-mL falcon tube and spun
for5 minat134 g.Tissuecultureplates(Nunc,Invitrogen,Paisley,UK)
or 13-mm
2 glass coverslips in 24-well plates (Nunc, Invitrogen) for
immunohistochemistry were precoated with 10 lg⁄mL poly(d-lysine)
(Sigma Aldrich, Dorset, UK). Cells were plated at a density of 2 · 10
6
per well in six-well plates for protein and RNA isolation, 0.5 · 10
6 per
well in 24-well plates for immunohistochemistry and enzyme-linked
immunosorbent assays (ELISAs), and 0.5 · 10
5 cells per well in
96-well plates for neuronal cell survival assays.
The neurons were grown in Neurobasal medium (Invitrogen,
Paisley, UK), supplemented with B-27 (Invitrogen, Paisley, UK),
2m m glutamine, 1.5% glucose, 100 lg⁄mL streptomycin and
60 lg⁄mL penicillin (Invitrogen) at 37 C in a humidiﬁed atmosphere
of 95% air and 5% CO2. Cultures were used after 7 days in vitro, and
were composed of > 98% neurons as judged by b-tubulin III staining.
All of the cultures used were similar in appearance at the time of
treatment. Dexamethasone (Sigma Aldrich, Dorset, UK) and the
retinoids were used in · 1000 stock concentrations in dimethylsulph-
oxide. The retinoids used have been previously described (Bernard
et al., 1992; Corcoran et al., 2000; Goncalves et al., 2009). They
were: atRA (Sigma Aldrich, Dorset, UK); two RARa selective
agonists (AM 580, referred to here as RARaa and BMS 194753,
referred to here as RARab); a RARa selective agonist (CD2019) and a
RARc selective agonist (CD437). All of the retinoid agonists were
synthesized by Sygnature Chemical Services (Nottingham, UK)
except for BMS 194753, which was provided as a gift by C. Zusi
of BMS. Culture conditions were three wells per treatment carried out
three times.
Neuronal survival
Ab1–40 and Ab1–42 (Californian Peptide Research, Napa, CA, USA)
were made up at · 1000 concentration in dimethylsulphoxide.
Neurons were cultured for 7 days in serum-free medium and then
for 3 days with 10 lm human Ab and either 0.01, 0.1 or 1 lm retinoid
agonist. Cell survival was assessed with a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Promega,
Southampton, UK), according to the manufacturer’s instructions.
Alternatively, at the end of the treatment period, the medium was
changed to PBS containing 50 lm propidium iodide (Sigma Aldrich)
and 250 lm Hoechst (Sigma Aldrich), and after 15 min the number of
viable cells was counted on an IN Cell Analyser 1000 (GE Healthcare,
Little Chalfont, Bucks, UK).
ELISAs
Ab1–40 and Ab1–42 were measured with sandwich ELISA kits
according to the manufacturer’s instructions [Wako Chemicals
(GmbH, Neuss, Germany) for mouse Ab, and Invitrogen for human
Ab]. Secreted Ab from the in vitro assays was measured by the direct
addition of the cell medium to the ELISA plates in the presence of
protease inhibitors (Calbiochem, Merck Chemicals, Nottingham, UK).
For measurement of intracellular Ab from the in vitro assays, the cells
were washed twice in PBS, and the Ab was extracted with 5 m
guanidine hydrochloride⁄50 mm Tris–HCl (pH 8.0). This was mixed
for 3–4 h at room temperature, and then diluted 1 : 20 in PBS
containing 5% bovine serum albumin and 0.03% Tween-20 and
centrifuged at 16 000 g for 20 min at 4 C. The supernatant was then
added to the ELISA plates in the presence of protease inhibitors. For
analysis of Ab in Tg2576 mice, animals were perfused with saline and
brains were dissected out. Cortices were then snap frozen and stored at
)80 C until use. For analysis of Ab, the cortices were homogenized in
10 volumes of ice-cold 5 m guanidine hydrochloride⁄50 mm Tris–
HCl (pH 8.0), and the samples were processed as above. Ab readings
were normalized to protein concentrations of the cells or brain tissue
used, in order to eliminate variability in cell numbers. The assays were
performed in triplicate for each animal.
RT and real-time PCR
RNAwas isolated as previously described (Corcoran et al., 2000), and
cDNA synthesis was carried out with an Amersham kit, according to
the manufacturer’s instructions. The following mouse primers were
used: ADAM10, forward, aaagaccctacaaatcctttcc; ADAM10, reverse,
gcttttctcacatattccccc (product length 192 bp); b-site of amyloid
precursor protein-cleaving enzyme (BACE1), forward, atcagtccttccg-
catcac; BACE1, reverse, gcaaagccaattcgctttc (product length 187 bp);
mouse c-secretase, forward, ctcatctacacgcccttcac; mouse c-secretase,
reverse, catcagggaggacatgatcag (product length 180 bp); and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), forward, cgtaga-
caaaatggtgaaggt; GAPDH, reverse, gactccacgacatactcagc (product
length 297 bp). Real-time PCR was performed using an SYBRGreen
kit (Roche Products, Nottingham, UK), and a Roche light cycler,
250 ng of cDNA and the speciﬁc primer pairs (0.5 lm each primer).
The quantitative PCR was performed as follows: heating to 95 C for
5 min, followed by 45 PCR cycles (one cycle contained the following
steps: 5 s at 95 C, 5 s at 55 C, and 15 s at 72 C). The speciﬁcity of
each primer pair was conﬁrmed by melting curve analysis and agarose
gel electrophoresis. The relative quantity of mRNA was calculated
from a GAPDH standard curve.
Antibodies
The following antibodies were used: rabbit a-ADAM10 (1 : 100;
Millipore, Livingston, UK), mouse anti-APP (1 : 200, 22C11; Milli-
pore), mouse anti-Ab (1 : 5000, 6E10; Covance, Emeryville, CA,
USA) and mouse anti-bIII tubulin (1 : 1000; Promega). Secondary
antibodies were AlexaFluor 594 (1 : 1000; Molecular Probes, Invitro-
gen, Paisley, UK) and AlexaFluor 680 (1 : 5000; Molecular Probes).
Immunohistochemistry and image analysis
Immunohistochemistry was carried out as previously described
(Goncalves et al., 2005). Neuronal cultures were washed with PBS
for 1 min. They were then ﬁxed in 4% paraformaldehyde for 30 min,
and washed three times for 5 min each in PBS–0.02% Tween. They
were incubated in primary antibody in PBS–0.02% Tween at 4 C
overnight. Primary antibody was removed by washing three times for
5 min each in PBS–0.02% Tween. They were incubated in the
secondary antibody for 1 h at room temperature in PBS–0.02%
Tween, and then washed in PBS three times for 5 min each. The ﬁrst
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dihydrochloride (DAPI) (1 lg⁄mL; Sigma Aldrich). The coverslips
were then mounted with FluroSave reagent (Merck, Hoddeson,
Hertfordshire, UK). Incubation of neurons with secondary antibodies
in the absence of primary antibodies produced a very weak diffuse
staining of cell bodies that did not overlap with the primary antibody-
speciﬁc staining (data not shown). Multichannel ﬂuorescence (DAPI–
ﬂuorescein isothiocyanate–Texas Red ﬁlter set) images were captured
with axiovision (release 4.6) imaging software and a Plan-Apochro-
mat ·20 0.75 NA objective ﬁtted to an ApoTome workstation
(Axioplan 2 imaging microscope with Apotome slider module,
motorized focus, and an AxioCam MRm cooled monochrome digital
camera set at 1388 · 1040 pixel resolution) (Carl Zeiss). Channels
were imaged sequentially to eliminate bleed-through, and multichan-
nel image overlays were obtained with adobe photoshop 7.0 (Adobe
Systems, San Jose, CA, USA).
Western blotting
Protein was isolated from the neuronal cultures in a lysis solution
containing 50 mm Tris–HCl (pH 7.6), 1% NP-40 (Sigma Aldrich),
150 mm NaCl and 2 mm EDTA, with 1 mm phenylmethylsulfonyl
ﬂuoride, in the presence of a protease inhibitor mixture (Sigma
Aldrich). Cell lysates were centrifuged for 10 min at 9 000 g
Extracellular protein was isolated from the treated Tg2576 mice as
previously described (Lesne et al., 2006). The protein concentration in
the supernatants was determined with the BCA Protein Assay (Pierce,
Rockford, IL, USA). Ten micrograms or 2.5 lg of protein was loaded
onto 8% SDS-PAGE gels. Wet blotting was performed, and the blots
were probed with 22C11 to detect full-length APP or 6E10 to detect
sAPPa. The membranes were then incubated with the secondary
antibody and visualized with an Odyssey infrared scanning system.
For a loading control, the blots were probed with mouse anti-bIII
tubulin and developed as above. Signal density was calculated as the
ratio of signal intensity to b-III tubulin.
Animal treatments
All procedures were performed in accordance with the Animal
Scientiﬁc Procedures Act 1986 (UK). Mice (129S2⁄SvHsd) were
purchased from Harlen, and Tg2576 mice on a 129S6 background were
purchased from Taconic Farms (Germantown, NY, USA). Mice were
maintained on a 12-h light⁄dark cycle at 20–22 C and given food and
water ad libitum. Mice were injected intraperitoneally with 1 mg⁄kg
retinoids three times a week from 3 to 7 months of age, or fed retinoids
at 3.6 mg⁄kg daily from 3 to 7 months of age. These doses were based
on previous work (Hind & Maden, 2004; Stinchcombe & Maden,
2008).For intraperitoneal studies, n = 5,and for feeding studies, n =3 .
In situ brain perfusion technique
The perfusion method was used as previously described (Sanderson
et al., 2008). Adult male 129S2⁄SvHsd mice (25 g) were anaes-
thetized [intraperitoneal medetomidine hydrochloride (2 mg⁄kg),
ketamine (150 mg⁄kg) and heparin (100 U)]. The ﬂow rate was
5m L⁄min for 10 min. AM 580 (Mr 355.2) was custom radiolabelled
with tritium (54.8 Ci⁄mmol, radiochemical purity 99.9%; Moravek,
Brea, CA, USA), and [
14C]sucrose (Mr 342, 498 mCi⁄mmol,
radiochemical purity ‡ 98%; Moravek). [
3H]AM 580 (4.6 nm) and
[
14C]sucrose (1.5 lm) were present in the artiﬁcial plasma. The
artiﬁcial plasma consisted of a modiﬁed Krebs–Henseleit mammalian
Ringer solution with the following constituents: 117 mm NaCl,
4.7 mm KCl, 2.5 mm CaCl2, 1.2 mm MgSO4, 24.8 mm NaHCO3,
1.2 mm KH2PO4,1 0m m glucose, and 1 g⁄L bovine serum albumin.
After perfusion, a cisterna magna cerebrospinal ﬂuid (CSF) sample
was taken, the animal was decapitated and the brain was removed.
Samples of the frontal cortex, occipital cortex, caudate putamen,
hippocampus, amygdala, hypothalamus, thalamus, pons, cerebellum
and fourth ventricle choroid plexus were taken. All of the brain matter
remaining after these samples had been taken was subjected to
capillary depletion analysis (Sanderson et al., 2008). In brief, a brain
homogenate was prepared, using a buffer and a dextran solution. The
ﬁnal dextran concentration was 13%. Centrifugation of this homog-
enate (5,400 g for 15 min at 4 C) produced an endothelial cell-
enriched pellet and a brain parenchyma-containing supernatant.
Capillary depletion (including brain homogenate, supernatant and
pellet), brain region, circumventricular organ, CSF and plasma
samples were solubilized with 3.5 mL of Solvable (Perkin Elmer,
Walthan, MA, USA; 0.5 mL). Lumasafe scintillation ﬂuid (Perkin
Elmer) was then added. Sample radioactivity was quantiﬁed (Packard
Tri-Carb 2900TR counter). Tissue radioactivity (d.p.m.⁄g) was
expressed as a percentage of that in plasma (d.p.m.⁄mL) and termed
RTissue (mL⁄100 g). Where stated, the RTissue for AM 580 has been
corrected for vascular⁄extracellular space by subtraction of the
[
14C]sucrose RTissue value. Blood-to-brain unidirectional rate constants
(Kin) were determined by single-time uptake analysis (Kin =[
14C]su-
crose-corrected RTissue values⁄perfusion time) after 10 min of perfu-
sion (Williams et al., 1996). [
14C]Sucrose is a baseline marker. In
brain samples, it provided a measurement of vascular space. Any
deviation from the norm indicated loss of BBB integrity. In the
choroid plexus, [
14C]sucrose provides measures of the vascular space
and extracellular spaces formed between the choroidal capillary
endothelium and epithelium.
Octanol⁄saline partition coefﬁcient
An octanol⁄saline partition coefﬁcient (pH 7.4) was determined for
[
3H]AM 580 (6.0 nm), using previously described methods (Sander-
son et al., 2008).
Data analysis
Data were analysed with Student’s t-test or one-way anova, followed
by Tukey’s test with sigma stat software (SPSS Software,




Fig. 1. Structure of the retinoid agonists. (A) atRA, a pan-agonist of all the
RARs. (B) AM 580, an RARa agonist. (C) BMS 194753, an RARa agonist.
(D) CD 2019, an RARb agonist. (E) CD 437, an RARc agonist.
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at a P-level of 0.05. Results are means ± standard errors (SEs), and
P-values are provided as summary statistics.
Results
It has previously been shown that the glucocorticoid dexamethasone
induces Ab production in mouse neuronal N2A cells (Green et al.,
2006) by altering APP processing. Therefore, to investigate the
potential role of retinoid signalling in Ab production, we treated
mouse embryonic day 15 cortical neurons with dexamethasone and
retinoid agonists (Fig. 1). Cortical neurons were cultured in serum-free
medium, and after 7 days, 0.1, 1 or 10 lm dexamethasone was added
to the cultures; 3 days later, both intracellular and extracellular Abwas
measured by sandwich ELISA. With increasing amounts of dexa-
methasone, there were increases in intracellular and extracellular Ab1-
40 as compared with vehicle-treated cultures (Fig. 2A and C;
intracellular Ab1–40, Student’s t-test, t4 = )7.23, P = 0.002, vehicle
vs. 10 lm dexamethasone; extracellular Ab1–40, Student’s t-test,
t4 = )12.00, P < 0.001, vehicle vs. 10 lm dexamethasone) and
increases in intracellular and extracellular Ab1–42 as compared with
vehicle-treated cultures (Fig. 2B and D; intracellular Ab1–42, Stu-
dent’s t-test, t4 = )10.60, P < 0.001, vehicle vs. 10 lm dexametha-
sone; extracellular Ab1–42, Student’s t-test, t4 = )16.28, P < 0.001,
vehicle vs. 10 lm dexamethasone). In order to establish whether RAR
agonists could prevent this Ab production caused by dexamethasone,
neurons were cultured as above, and on day 7, 10 lm dexamethasone
and 0.1 lm RARa, RARb or RARc agonist was added. After 3 days,
sandwich ELISAs to detect Ab1–40 and Ab1–42 were carried out. In
the presence of the RARaa agonist, there were signiﬁcant decreases in
the amounts of intracellular and extracellular Ab1–40 as compared
with 10 lm dexamethasone-treated cultures (Fig. 2A and C; intracel-
lular Ab1–40, one-way anova, P = 0.008, followed by Tukey’s test,
F3,8 = 8.28, P = 0.008; extracellular Ab1–40, one-way anova,
P < 0.001, followed by Tukey’s test, F3,8 = 25.81, P = 0.006) and
of intracellular and extracellular Ab1–42 as compared with 10 lm
dexamethasone-treated cultures (Fig. 2B and D; intracellular Ab1–42,
one-way anova, P < 0.001, followed by Tukey’s test, F3,8 = 32.24,
P < 0.001; extracellular Ab1–42, one-way anova, P < 0.001, fol-
lowed by Tukey’s test, F3,8 = 35.84, P < 0.001). In contrast RARb
AB
CD
Fig. 2. RARa signalling prevents both intracellular and extracellular Ab accumulation. Cortical neurons were cultured in the presence of either 0.1, 1 or 10 lm
dexamethasone (Dex) with or without 0.1 lm retinoids for 3 days; they were then assayed for intracellular and extracellular Ab1–40 and Ab1–42 by ELISA.
(A) Intracellular Ab1–40. (B) Intracellular Ab1–42. (C) Extracellular Ab1–40. (D) Extracellular Ab1–42. With increasing amounts of dexamethasone, there were
increases in both extracellular and intracellular Ab1–40 and Ab1–42 accumulation as compared with control cultures. In the presence of RARa agonist and 10 lm
dexamethasone, there were decreases in the amounts of both extracellular and intracellular Ab1–40 and Ab1–42 as compared with the 10 lm dexamethasone-treated
cultures. Student’s t-test for dose–response study and one-way anova followed by Tukey’s test for comparison between retinoid treatments. Results are mean ± SE
(n =3 ;* P < 0.05, **P < 0.005, ***P < 0.001).
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extracellular levels of Ab1-40 and Ab1-42 as compared with
dexamethasone-treated cultures (Fig. 2A–D; one-way anova fol-
lowed by Tukey’s test as above, all P > 0.05).
Previous work has shown that dexamethasone increases Ab produc-
tion by increasing levels of both APP and BACE1 (Green et al., 2006).
Therefore,wenextinvestigated whetherRARasignallingwasaffecting
totalAPPlevelsand⁄orthoseoftheenzymesinvolvedinitsprocessing.
On western blotting, there was no signiﬁcant increase in total APP
expression in dexamethasone-treated cultures as compared with dexa-
methasone⁄retinoid agonist-treated cultures (Fig. 3A and B; one-way
anova, P = 0.76, F3,8 = 0.392, all P > 0.05).
By immunohistochemistry, there was an increase in the number of
cortical neurons expressing the a-secretase ADAM10 in the presence
of 0.1 lm atRA as compared with vehicle-treated cultures (Fig. 4A
and B; one-way anova, P < 0.001, followed by Tukey’s test,
F5,12 = 75.10, P = 0.016). In neurons cultured in the presence of
either 0.1 lm RARaa or 0.1 lm RARab, there was also a signiﬁcant
increase in ADAM10 expression as compared with vehicle-treated
cultures (Fig. 4A and B; one-way anova, followed by Tukey’s test as
above, RARaa and RARab, P < 0.001), whereas neither RARb nor
RARc agonists affected ADAM10 expression as compared with
vehicle-treated cultures (Fig. 4A and B; one-way anova, followed by
Tukey’s test as above, P > 0.05). These data were conﬁrmed by light
cycler RT-PCR (Fig. 4C); the RARaa agonist increased ADAM10
expression as compared with vehicle-treated cultures (Fig. 4C; one-
way anova, P < 0.001, followed by Tukey’s test, F3,8 = 278,
P < 0.001), whereas neither RARb or RARc agonists affected
ADAM10 expression as compared with vehicle-treated cultures
(Fig. 4C; one-way anova, followed by Tukey’s test as above, all
P > 0.05). None of the retinoids affected b-secretase expression as
compared with vehicle-treated cultures (Fig. 4C; one-way anova,
P = 0.005, F3,8 = 5.20, all P > 0.05) or c-secretase expression as
compared with vehicle-treated cultures (Fig. 4C; one-way anova,
P = 0.265, F3,8 = 1.38, all P > 0.05). These data suggest that RARa
signalling processes the APP into the non-amyloidic pathway by
upregulating ADAM10 expression and that none of the agonists
affects the amyloidic pathway.
Given that the a-secretase products are neuroprotective (Allinson
et al., 2003), we investigated whether RARa signalling could prevent
Ab-induced neuronal cell death. Cortical neurons were cultured in
serum-free medium for 7 days, and then in the presence of 10 lm
human Ab1–42 alone or in combination with either 0.01, 0.1 or 1 lm
retinoid agonist. Three days later, neuronal cell death was assessed
with an MTTassay. In the presence of Ab1–42, there was a signiﬁcant
amount of neuronal cell death as compared with the control cultures
(Fig. 5; Student’s t-test, t4 = )3.47, P = 0.003). This cell death could
be prevented by the RARa agonists, where there was increasing
neuronal cell survival with increasing dose of the agonist (Fig. 5;
Student’s t-test, t4 = )3.38, P = 0.004 for 1 lm RARaa; Student’s
t-test, t4 = )3.47, P=0.003 for 1 lm RARab). With increasing dose
of the RARb agonist, there was little or no effect on cell survival
(Fig. 5; Student’s t-test, t4 = )0.37, P = 0.071 for 1 lm RARb), and
only the highest concentration of RARc used had an effect that
contributed to cell death (Fig. 5; Student’s t-test, t4 = 3.02, P = 0.008
for 1 lm RARc). Similar data were obtained with the use of
propidium iodide and Hoescht (data not shown).
To assess whether retinoid agonists could be used to affect Ab load
in vivo, we investigated whether retinoids could pass through the BBB
by using [
3H]AM 580 (Fig. 6) and an in situ brain perfusion technique
in anaesthetized mice. All [
14C]sucrose values in the brain regions,
capillary depletion and choroid plexus samples were as expected.
There was a signiﬁcant difference between the values obtained for
[
3H]AM 580 and [
14C]sucrose in all brain region and capillary
depletion samples (Fig. 6; one-way anova on ranks, P<0.001,
followed by Tukey’s test, P<0.05, for both brain region samples and
capillary depletion samples; one degree of freedom). The amount of
[
3H]AM 580 (78.7 ± 6.7%, n = 5, corrected for vascular space) in the
amygdala was approximately 32 times greater than the amount of
[
14C]sucrose, and was signiﬁcantly lower (one-way repeated measures
anova, P<0.001, F8,88 = 6.848, followed by Tukey’s test) than that
in the hypothalamus (P<0.001), caudate nucleus (P=0.001),
occipital cortex (P=0.006), frontal cortex (P=0.016) and cerebel-
lum (P=0.016) (Fig. 6). The Kin value for [
3H]AM 580 ranged from
78.7 ± 6.7 lL⁄min per g in the amygdala to 142.7 ± 23.7 lL⁄min
per g in the hypothalamus. [
3H]AM 580 was also detected in the CSF
at higher levels than [
14C]sucrose (3.6 ± 0.67%, [
14C]sucrose values
removed; n = 3). [
3H]AM 580 was found at very high levels in the
choroid plexus, RTissue values reaching 993.1 ± 78.0% (n =5 ;
[
14C]sucrose values corrected). The octanol⁄saline partition coefﬁ-
cient measured for [
3H]AM 580 was 207.8 ± 38.0% (n = 3).
Having established that retinoids can cross the BBB, we investi-
gated whether any of the retinoid agonists had an effect on the Ab load
in Tg2576 mice, which overexpress the Swedish mutation of APP,
leading to increased Ab levels (Hsiao et al., 1996). They were injected
intraperitoneally three times a week with 1 mg⁄kg of either vehicle,
A
B
Fig. 3. Effect of retinoids on APP expression. Cortical neurons were cultured
in serum-free medium for 7 days, and then treated with 10 lm dexamethasone
with or without 0.1 lm retinoid agonists for 3 days. (A) Western blot of total
APP. (B) Quantiﬁcation of total APP. There was no signiﬁcant change in total
levels of APP in the presence of any of the retinoid agonists as compared with
dexamethasone-treated cultures. One-way anova. Results are mean ± SE
(n = 3).
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3.6 mg⁄kg of either RARaa or RARab. We ﬁrst investigated whether
there was an increase in cortical extracellular sAPPa protein, which is
a product of a-secretase processing (Thinakaran & Koo, 2008) by
RARa signalling. By western blotting, there was a signiﬁcant increase
in the levels of this protein in the RARa agonist-treated mice as
compared with the vehicle-treated ones (Fig. 7A and B; one-way
anova, P < 0.01, followed by Tukey’s test, F3,8 = 129, P < 0.001),
whereas the RARb or RARc agonists had no effect on this protein as
compared with the vehicle-treated mice (Fig. 7A and B; one-way
anova, followed by Tukey’s test as above, P > 0.05).
To conﬁrm that the increase in sAPPa levels caused by RARa
signalling correlated with a decrease in Ab levels, we carried out
ELISAs for Ab1–40 and Ab1–42. In the cortices, there was a
signiﬁcant decrease in the amounts of both Ab1–40 and Ab1–42 in
the RARa agonist-treated mice given agonist intraperitoneally as
compared with the vehicle-treated ones (Fig. 8A; for Ab1–40 levels,
one-way anova, P<0.001, followed by Tukey’s test, F3,8 = 68.40,
P < 0.001; for Ab1–42 levels, one-way anova, P<0.001, followed
by Tukey’s test, F3,8 = 33.90, P < 0.001) or orally as compared with
the vehicle-treated ones (Fig. 8B; for Ab1–40 levels, one-way anova,
P < 0.001, followed by Tukey’s test, F2,12 = 810, all P < 0.001; for
Ab1–42 levels, one-way anova, P < 0.001, followed by Tukey’s test,
F2,12 = 352, all P < 0.001). There was no signiﬁcant difference
A
B C
Fig. 4. Effect of retinoids on secretases involved in APP processing. Cortical neurons were cultured in serum-free medium for 7 days, and then treated with 0.1 lm
retinoid agonist for 3 days. (A) Immunohistochemistry of ADAM10 expression. (B) Quantiﬁcation of ADAM10 expression. (C) Lightcycler RT-PCR of ADAM10,
b-secretase and c-secretase; RARa signalling increased ADAM10 expression, whereas none of the retinoids altered the levels of b-secretase or c-secretase. Student’s
t-test. Results are mean ± SE (n =3 ;* P < 0.05, ***P < 0.001). Scale bar – 50 lm.
Fig. 5. Effect of retinoids on Ab-mediated neuronal cell death in cortical
neuronal cultures. Cortical neurons were cultured in serum-free medium for
7 days, and then treated with 10 lm Ab1-42 alone or with either 0.1, 1 or 1 lm
retinoid agonist for 3 days. Cell survival was measured by an MTTassay. In the
presence of 10 lm Ab1–42, there was a signiﬁcant amount of neuronal cell
death as compared with control cultures; this could be attenuated by RARa
signalling, but not by RARb or RARc signalling. Student’s t-test. Results are
mean ± SE (n =3 ;* P < 0.05, **P < 0.005).
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treated Tg2576 mice as compared with the vehicle-treated ones
(Fig. 8A; one-way anova, followed by Tukey’s test as above for
intraperitoneal treatment, all P > 0.05).
We ﬁnally investigated whether in vivo levels of ADAM10,
b-secretase and⁄or c-secretase were altered by the retinoids. By
light cycler RT-PCR, there was a signiﬁcant increase in ADAM10
expression in RARaa agonist-treated mice as compared with vehicle-
treated ones (Fig. 8C; one-way anova, P < 0.001, followed by
Tukey’s test, F3,8 = 60.06, P<0.001), whereas RARb or RARc
agonists had no effect on its expression (Fig. 8C; one-way anova
followed by Tukey’s test as above, P > 0.05). None of the retinoid
agonists affected b-secretase (Fig. 8C; one-way anova, P = 0.11,
F3,8 = 2.32, all P > 0.05) or c-secretase (Fig. 8C; one-way anova,
P = 0.06, F3,8 = 3.00, all P > 0.05) expression as compared with the
vehicle-treated mice. These data suggest that the increase in a-secretase
Fig. 6. Retinoids can cross the BBB. [
3H]AM 580 was prepared with two tritium labels, one each in the 2 and 3¢ positions, as shown. The graph shows [
3H]AM 580
and [
14C]sucrose (vascular space marker) detected in brain regions and parenchyma (supernatant) and capillary endothelial cells (pellet) after capillary depletion
analysis of the whole brain homogenate relative to that in the plasma (RTissue;m L⁄ 100 g). One-way anova on ranks, P < 0.001, followed by Tukey’s test, P <0.05
for both brain region samples and capillary depletion samples. Results are mean ± SE (n = 3–5; *P < 0.05 for [




Fig. 7. RARa signalling increases sAPPa production in Tg2576 mice. Mice were injected intraperitoneally with 1 mg ⁄ kg retinoids from 3 to 7 months of age every
3 days. (A) Western blot of sAPPa production in cortices. (B) Quantiﬁcation of sAPPa production in cortices. There was a signiﬁcant increase in sAPPa production
in the RARa agonist-treated mice as compared with the vehicle-treated ones, whereas the other RAR agonists had no effect on its production. One-way anova,
followed by Tukey’s test. Results are mean ± SE (n =3 ;* P < 0.05).
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expression, and this leads to APP being processed into the non-
amyloidic pathway, resulting in decreased Ab1–40 and Ab1–42
production in the Tg2576 mice.
Discussion
Previous work has shown that the loss of RA signalling in the rat
caused by dietary deﬁciency of vitamin A can cause Ab deposition
(Corcoran et al., 2004) and alterations in enzymes involved in APP
processing (Husson et al., 2006), and that there is a loss of RARa
expression in AD human pathology samples (Corcoran et al., 2004).
Recent data have shown that atRA, a pan-agonist of the RARs, given
intraperitoneally to a mouse model of AD can reduce Ab levels (Ding
et al., 2008). By using the glucocorticoid dexamethasone, we have
shown here that the production of Ab is increased in embryonic mouse
cortical neurons, and similar data have been obtained in N2A and
PC12 cells (Snyder et al., 2005; Green et al., 2006), further
highlighting the association between stress hormones and AD (Dong
& Csernansky, 2009). The increase in Ab can be attenuated by
RA signalling, and we have shown here that it is RARa as opposed
to RARb and RARc signalling that carries out this role.
One mechanism through which RARa signalling acts is by
modulating the processing of APP into the non-amyloidic rather than
the amyloidic pathway, without affecting the overall levels of APP. In
the non-amyloidic pathway, APP can be cleaved by a-secretases into a
soluble neuroprotective fragment (Allinson et al., 2003), and one of
these, ADAM10, has beenshownto be regulated by RA (Prinzen et al.,
2005; Koryakina et al., 2009; Tippmann et al., 2009), and this may be
a direct action, as the promoter of this gene contains an RA response
element (Prinzen et al., 2005). ADAM10 cleaves the APP located on
the cell surface, thus preventing the build-up of extracellular Ab
(Allinson et al., 2003). Although RAR needs to heterodimerize with
RXR in order to activate gene transcription, RXR agonists alone do not
induce ADAM10 expression, suggesting that RAR agonists are
essential for its expression (Tippmann et al., 2009). Here we have
shown both in vitro and in vivo, that RARa signalling increases
ADAM10 expression, whereas neither RARb nor RARc activation
have little or no effect on its expression. In the amyloidic pathway, APP
is cleaved by b-secretase and c-secretase (Thinakaran & Koo, 2008),
which we have shown are not regulated by any of the retinoid agonists.
In addition to RARa signalling decreasing extracellular Ab,w e
have demonstrated here that it also decreases intracellular Ab. It has
been shown that intraneuronal Ab plays a role in cognitive dysfunc-
tion (Billings et al., 2005), and that intraneuronal Ab leads to neuronal
cell death (Kienlen-Campard et al., 2002). The source of this
intracellular Ab may be secreted Ab that is taken back into the cell,
or non-secreted Ab (LaFerla et al., 2007). Retinoids have already been
shown to be neuroprotective (Wuarin & Sidell, 1991; Ahlemeyer
et al., 2001; Corcoran et al., 2002, 2004; Hagglund et al., 2006), but
the mechanism by which they achieve this has not yet been shown.
Given that RARa agonists increase APP processing into the non-
amyloidic pathway and that this gives rise to a neuroprotective
fragment, this may help to prevent Ab toxicity.
AB
C
Fig. 8. RARa signalling prevents Ab accumulation in Tg2576 mice by upregulating ADAM10 expression. Mice were injected intraperitoneally with 1 mg ⁄ kg
retinoids from 3 to 7 months of age every 3 days, or they were fed RARa agonists, 3.6 mg ⁄ kg, from 3 to 7 months of age. Ab1–40 and Ab1–42 levels were
measured by ELISA. (A) Ab1–40 and Ab1–42 levels in intraperitoneal RAR agonist-treated mice. (B) Ab1–40 and Ab1–42 levels in RARa agonist-fed mice.
(C) Expression of secretases in intraperitoneal RAR agonist-treated mice. There were signiﬁcant decreases in Ab1–40 and Ab1–42 levels in the RARa agonist-
treated mice as compared with the vehicle-treated ones, whereas the other RAR agonists did not alter Ab load. In only the RARa agonist-treated mice was there a
signiﬁcant increase in ADAM10 expression as compared with the vehicle-treated ones; none of the retinoid agonists affected b-secretase or c-secretase. One-way
anova, followed by Tukey’s test. Results are mean ± SE (n = 3–5; ***P < 0.001).
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3H]AM
580 can be detected in the brain parenchyma and in the cerebral
capillary endothelial cells, indicating detectable BBB passage. It can
be estimated that 2.5 ± 0.2% of the injected dose of [
3H]AM 580
reaches 1 g of murine brain in 10 min. This relatively high distribution
to the brain is likely to be partly associated with the considerable
lipophilicity of [
3H]AM 580 as measured by the octanol⁄saline
partition coefﬁcient.
In addition, there was signiﬁcant variation in the regional brain
distribution of [
3H]AM 580 as shown by differences in Kin values.
This may be related to the differential localization of transporters for
[
3H]AM 580 at the BBB. Interestingly, STRA6 is a multitransmem-
brane domain protein that has been demonstrated to be involved in
retinol absorption in bovine retinal pigment epithelial cells (Bouillet
et al., 1997; Kawaguchi et al., 2007). STRA6-expressing capillaries
are found speciﬁcally in the striatum, preoptic zone, medial
cerebellar nuclei and ventral cochlea nuclei, and STRA6 is also
densely expressed in the choroid plexus (Bouillet et al., 1997). Thus,
it is of interest that a signiﬁcant amount of [
3H]AM 580 was
associated with the murine choroid plexus samples; however, it has
not been determined whether STRA6 can bind the retinoid agonists.
Our study shows that [
3H]AM 580 is able to cross the blood–CSF
barrier and be detected in the CSF. It is important to note that CSF
concentrations are considered to reﬂect unbound drug concentrations
in brain interstitial ﬂuid (Liu et al., 2009).
We have used two different structural classes of RARa agonists,
which give the same results in vivo, strongly pointing to this being an
RARa action. The administration of the RARa agonist in vivo,a s
in vitro, leads to an upregulation in ADAM10 expression and a
reduction in Ab production. We have shown that, by giving the
retinoid agonists to the Tg2576 mice either intraperitoneally or orally
for 3 months from 3 to 7 months of age, a period when there is a
dramatic increase in Ab production (Kawarabayashi et al., 2001), this
is prevented. An orally given drug would be an attractive therapeutic
agent for AD, and we note that there was a greater decrease in Ab
production with the oral than with the intraperitoneal route. On the one
hand, this may be because the oral dosing was continuous, such that
the drug was not cleared; on the other hand, it may be that the oral
dose was simply higher than the intraperitoneal dose.
In summary, we have shown here that RARa agonists have multiple
effects on pathways in AD. They process APP into the non-amyloidic
pathway, they decrease intracellular Ab production, and they are
neuroprotective. Given the diversity of these roles, we suggest that
RARa agonists have therapeutic potential for the treatment of AD, and
have clear advantages over current drugs, such as cholinesterase
inhibitors, which may target only one aspect of the disease.
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